A test that is able to confirm or rule out Alzheimer's disease has been validated and standardised by researchers at the University of Pennsylvania School of Medicine.
The test can also predict if a person's mild cognitive impairment would change to Alzheimer's disease over time.
It can do this by measuring cerebrospinal fluid concentrations of two of the disease's biochemical signifiers named amyloid beta42 peptide and tau protein.
"Validated biomarker tests will improve the focus of Alzheimer's clinical trials, enrolling patients at earlier stages of the disease to find treatments that can at least delay ... neurodegeneration," said Dr Leslie Shaw, co-director of the Penn Alzheimer's Disease Neuroimaging Initiative Biomarker Core.
Dr Shaw led the team of Penn Medicine researchers, who were able to detect the disease at the earliest stages, even before dementia symptoms showed up.
According to the Alzheimer's Society, there are more than 100 types of dementia, with Alzheimer's being the most common.
Please click here for advice to help you find the right type of care.